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Abstract
Introduction: The etiology of several hepatocellular carcinoma (HCC) cases remains largely unknown. Although Fasciola 
hepatica has been associated with liver fibrosis in Latin America, it has not yet been associated with HCC. This study aimed to 
determine the existence of specific IgG antibodies against F. hepatica in the serum samples of HCC patients. Methods: In total, 
13 serum samples from 13 HCC patients were screened using Fas2-ELISA. Results: Fas2-ELISA demonstrated negative results 
in all HCC patients included in this study. Conclusions: The pre-existence of F. hepatica infection in HCC patients needs to be 
further investigated in epidemiological and experimental studies.
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More than 20% of cancers in the developing world 
are associated with an infectious etiology, including 
hepatocellular carcinoma (HCC) from hepatitis B and C viruses, 
cholangiocarcinoma (CCA) from the liver fluke Opisthorchis 
viverrini, and gastric adenocarcinoma from the bacteria 
Helicobacter pylori. According to the International Agency for 
Research on Cancer (IARC), liver and intrahepatic bile duct 
cancers are the second-most lethal cancers in the world, causing 
nearly 750,000 deaths in 20121. In South America, liver cancer is 
the tenth-most fatal cancer. In Peru (a country in South America 
with the second highest liver cancer incidence rate), a total 
of 1,767 new cases of liver cancer were diagnosed and 1,716 
liver cancer-associated deaths were reported in 2012, making 
it the fifth-most fatal type of cancer in the country1. Given 
the high mortality and poor survival rates of this malignancy 
when diagnosed during the late stages, there is an urgent and 
imminent need to improve our understanding of the biology of 
this disease in order to facilitate the discovery of new pathways 
and therapeutic options. The prevalence and etiology of the two 
types of liver cancer are different. HCC is the most common type 
of liver cancer in the world and is associated with viral hepatitis 
infection and aflatoxin consumption. On the other hand, CCA 
is a rare malignancy that is very uncommon in South America 
and is associated with fluke infections in Asia. Interestingly, 
Peru has the highest incidence of primary liver cancer in South 
America, but such numbers cannot be fully attributed to HBV 
infections and aflatoxins, which are uncommon2,3. Although 
the prevalence of HCC and CCA in Peru is not independently 
defined, the existence of both is recognized in the Andean 
region4. Some evidence also indicates that the etiological factors 
behind a number of reports remain unknown5. While obesity 
and alcohol consumption do not appear to play a role in liver 
carcinogenesis in Peru, the involvement of other unrecognized 
etiological agents does seem plausible. 
Liver cancer is highly prevalent in the Andean region 
where some infectious diseases are geographically distributed 
in similar locations. This is linked to the liver fluke Fasciola 
hepatica that is endemic to the cattle-raising areas of the Andean 
region6. Recent evidence shows that liver cancer in Peru may be 
associated with an etiological factor different from HBV, given 
that a large proportion of the disease is neither serologically 
positive for HBV infection nor identifies an infectious disease 
as a bona fide etiological factor5,7. 
It is well known that the carcinogenic liver fluke O. viverrini, 
a close relative of F. hepatica, is a risk factor for CCA8. The 
biology of O. viverrini-associated CCA has been described and 
investigated thoroughly9. Moreover, the tissue damage caused by 
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O. viverrini and a number of metabolites and growth promoting 
proteins secreted by the liver fluke are recognized carcinogenic 
promoter factors10.  
Although the liver fluke O. viverrini has been associated 
with cancer in Asia, the role of F. hepatica in carcinogenesis 
remains unknown11. In preliminary reports, F. hepatica has been 
shown to cause hepatic damage by inducing fibrosis in the liver 
parenchyma and by upregulating the genes for liver fibrosis 
and cirrhosis in infected animals12. As liver fibrosis is widely 
known to be a major risk factor for liver cancer, we postulate 
that a history of Fasciola infection may be associated with liver 
cancer in Peru. 
In order to investigate our hypothesis, we assessed the 
existence of circulating antibodies against the F. hepatica Fas2 
antigen in patients diagnosed with liver cancer by conducting 
Fas2-ELISA, an accurate serological test based on the detection 
of circulating immunoglobulin G (IgG) antibodies elicited in 
infected individuals against Fas2. A total of 13 serum samples 
were analyzed. These biospecimens were previously obtained 
from an HCC study conducted at the Instituto Nacional 
de Enfermedades Neoplásicas (INEN). All the samples 
corresponded to patients diagnosed with liver cancer at INEN 
between 2014 and 2015. Written informed consent was obtained 
from each patient before sample collection. Demographic data 
was also recorded, which included the sex, age, tumor type, 
place of current residency, and place of birth. Serum samples 
were preserved at -80°C under laboratory conditions at INEN 
until delivery to the Laboratorios de Investigación (LID) at the 
Universidad Peruana Cayetano Heredia (UPCH) for testing. 
The Fas2-ELISA test was conducted at UPCH as described 
previously13. Briefly, Fas2 (300ng/well) was bound to microtiter 
plates Immulon® 4HBX (Dynex Technologies, Inc., Chantilly, 
VA, USA) via incubation for 16 hours at 4°C. The plates were 
washed five times with Phosphate Buffered Saline  (PBS) 
containing 0.05% Tween-20 (PBST) and then incubated in 2% 
Bovine Serum Albumin (BSA) in PBST (PBSTB) for 1 hour 
at 37°C. Serum (100μL) that was previously diluted (1/500 
in PBSTB) was added to the well and incubated for 1 hour at 
37°C. The plates were washed five times with PBST. Next, goat 
anti-human IgG conjugated to horseradish peroxidase (100μL) 
was diluted to 1/2000 in PBSTB, added to each well, and then 
incubated for 1 hour at 37°C. A color reaction developed when 
3,3',5,5'-tetramethylbenzidine (TMB) was incorporated into the 
reaction, which was stopped by adding 50mL of 2M H2SO4. The 
optical density was measured at 450nm in a microplate reader 
(Benchmark Bio-Rad). Negative and positive controls were 
used. The results obtained using Fas2-ELISA were analyzed 
considering the demographic and relevant clinical data of each 
patient. 
Ethical considerations
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The main characteristics of the study patient group are 
shown in Table 1. The mean age of the 13 patients was 41 years 
(range, 22-84). Four women and 9 men were included in the 
study. Eight (61.5%) patients were born in the Andean region of 
Peru (endemic areas for Fasciola), whereas the other 5 (38.5%) 
patients were born in non-endemic areas for Fasciola. Twelve 
patients had HCC as the primary tumor and 1 patient had a 
metastatic CCA located in the liver.
The Fas2-ELISA test was performed on the 13 study samples 
along with a positive and negative control. The reference values 
were established as optical density (OD) ≥ 0.2 for positive results 
and OD < 0.2 for negative results. The OD of the 13 study 
samples ranged from 0,019 to 0,156, demonstrating negative 
Fas2-ELISA results for all the analyzed samples.
Increasing evidence suggests the existence of etiological 
agents other than HBV and aflatoxins with respect to HCC 
incidence in Peru14. Given the close phylogenetic relationship 
of the carcinogenic liver fluke O. viverrini with F. hepatica, we 
hypothesized that the latter may be involved in idiopathic cancer 
in Peru. To explore our hypothesis, we assessed the existence of 
F. hepatica in a group of 13 patients diagnosed with liver cancer. 
The validated and accurate Fas2-ELISA test (a currently used 
routine serological test for Fasciola infection in Peru) was used 
to examine the existence of the circulating F. hepatica anti-Fas2 
ligand. Our results showed that F. hepatica was absent in the 
serum samples analyzed in this study. Although the study showed 
negative results, exposure and previous fascioliasis cannot be 
discarded as valid factors. F. hepatica-infected animals usually 
increase the amount of circulating and highly-specific anti-Fas2 
IgG antibodies, thus allowing the disease to be detected as early as 
10 days after infection using Fas2-ELISA15. However, anti-Fas2 
IgGs are short-lived and have an estimated half-life of less than 
6 months13, which does not allow for the accurate detection of 
F. hepatica using Fas2-ELISA 6 months post-infection. Therefore, 
our results need to be interpreted with caution.
In conclusion, none of the analyzed samples in this study 
showed the presence of antibodies against F. hepatica at the 
time of the test, suggesting that either the HCC patients were 
not recently infected or that they probably acquired the infection 
up to 6 months before sample collection. Whether fascioliasis 
is a condition that promotes liver cancer as a long-term effect 
is something that needs to be evaluated via epidemiological 
studies and experimental assays. 
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TABLE 1: Summary of study patient group characteristics.
Patient number Age Sex Tumor type Living place Birth place OD value*  
(Fas2-ELISA)
Fas2-ELISA  
result
1 24 M HCC Lambayeque Lambayeque 0.047 Negative
2 41 M HCC Lima Lima 0.152 Negative
3 37 F HCC Lima Lima 0.064 Negative
4 18 M HCC Lima Junín 0.066 Negative
5 33 M HCC Lima Lima 0.021 Negative
6 30 M HCC Huancavelica Huancavelica 0.019 Negative
7 27 M HCC Junín Junín 0.055 Negative
8 61 M HCC Cusco Cusco 0.052 Negative
9 22 F HCC Ayacucho Ayacucho 0.098 Negative
10 58 M HCC Junín Junín 0.09 Negative
11 81 M HCC Lima Huánuco 0.045 Negative
12 84 F CCA with liver 
metastases
Lima Lima 0.023 Negative
13 23 M HCC Huánuco Huánuco 0.04 Negative
OD: optical density; Fas2-ELISA: enzyme-linked immunosorbent assay; M: male; F: female; HCC: hepatocellular carcinoma; CCA: cholangiocarcinoma. 
*OD measured at 450nm.
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